BOTHELL, Wash., June 24, 2013 /PRNewswire/ -- BioLife Solutions, Inc. (OTC:BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media for cells and tissues, and contract aseptic media manufacturer, today announced that it has been named by Seattle Business Magazine as one of the best places to work in Washington state.
Now in its 23rd year, this competition salutes Washington companies setting the standard for leadership, strong benefits, ideal work environment, innovative training, happiest employees and more. Winners were recognized at an awards dinner held on June 20th at the Westin Hotel in Seattle.
Mike Rice, Chief Executive Officer, commented, "Our entire team is very honored and proud to receive this recognition. It is gratifying to see our people and special corporate culture acknowledged within the Washington state business community. We have built a very solid, high performance team that is the single greatest contributor to the success BioLife has achieved since the Company relocated to Bothell in early 2007. I'm honored to have the opportunity to lead such a dedicated and capable team."
In 2012, BioLife doubled revenue over 2011, doubled the size of its workforce to nearly 30 team members, and firmly established its products as best in class, clinical grade biopreservation storage and freeze media for cells, tissues, and organs. Shares of the Company have recently traded at nearly 10 times above a previous low price set in January 2011.
Rice continued, "BioLife is a very special place to work. A requirement for teamwork and open and honest communication is a hallmark of our merit-based culture and a foundational principal of my management philosophy."
For the complete list of winning companies, please visit: http://seattlebusinessmag.com.
About BioLife SolutionsBioLife Solutions develops, manufactures and markets patented hypothermic storage and cryopreservation solutions for cells and tissues. The Company's proprietary HypoThermosol® and CryoStor® platform of solutions are highly valued in the biobanking, drug discovery, and regenerative medicine markets. BioLife's products are serum-free and protein-free, fully defined, and are formulated to reduce biopreservation-induced cell damage and death. BioLife's enabling technology provides academic and clinical researchers, and commercial companies significant improvements in post-thaw cell, tissue, and organ viability and function. For more information please visit www.biolifesolutions.com, and follow BioLife on Twitter.
This news release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements include any statements that relate to the intent, belief, plans or expectations of the Company or its management, or that are not a statement of historical fact. Any forward-looking statements in this news release are based on current expectations and beliefs and are subject to numerous risks and uncertainties that could cause actual results to differ materially. Some of the specific factors that could cause BioLife Solutions' actual results to differ materially are discussed in the Company's recent filings with the Securities and Exchange Commission. BioLife Solutions disclaims any obligation to update any forward-looking statements as a result of developments occurring after the date of this press release. Media Relations:
Investor Relations:Len Hall
Matt ClawsonAllen & Caron Inc
Allen & Caron Inc(949) 474-4300
|SOURCE BioLife Solutions, Inc.|
Copyright©2012 PR Newswire.
All rights reserved